Department of Health Sciences, Université du Québec à Rimouski, Lévis, Quebec, Canada
Population Heath and Optimal Health Practices Axis, CHU de Québec-Université Laval Research Center, Quebec, Quebec City, Canada.
BMJ Open. 2022 May 31;12(5):e062197. doi: 10.1136/bmjopen-2022-062197.
Antidepressant drugs are the most frequently prescribed medication for mental disorders. They are also used off-label and for non-psychiatric indications. Prescriptions of antidepressants have increased in the last decades, but no systematic review exists on the extent of their use in the community.
We will conduct a systematic review to estimate the prevalence of antidepressant use in the community. We will search for studies published from 1 January 2010 in the Embase and MEDLINE databases using a combination of controlled vocabulary and keywords adjusted for each database without any language restriction. The main inclusion criterion is the presence of prevalence data of antidepressant utilization. Thus, we will include all studies with a descriptive observational design reporting the prevalence of antidepressant use in the community. Study selection (by title/abstract and full-text screening) and data extraction for included studies will be independently conducted by pairs of reviewers. We will then synthesize the data on the prevalence of antidepressant use in individuals living in the community. If possible, we will perform a meta-analysis to generate prevalence-pooled estimates. If the data allows it, we will conduct subgroup analyses by antidepressant class, age, sex, country and other sociodemographic categories. We will evaluate the risk of bias for each included study through a quality assessment using the Joanna Briggs Institute Critical Appraisal tool: Checklist for Studies Reporting Prevalence Data. DistillerSR software will be used for the management of this review.
Ethical approval is not required for this review as it will not directly involve human or animal subjects. The findings of our systematic review will be disseminated through publications in peer-reviewed journals, the Qualaxia Network (https://qualaxia.org), presentations at international conferences on mental health and pharmacoepidemiology, as well as general public events.
CRD42021247423.
抗抑郁药是治疗精神障碍最常开的处方药物。它们也被超适应证使用，用于非精神科适应证。过去几十年中，抗抑郁药的处方量有所增加，但尚无针对其在社区中使用范围的系统评价。
我们将进行系统评价，以估计社区中抗抑郁药使用的流行率。我们将使用 Embase 和 MEDLINE 数据库中的组合控制词汇和关键词进行搜索，这些词汇针对每个数据库进行了调整，没有任何语言限制。主要纳入标准是存在抗抑郁药利用的流行率数据。因此，我们将纳入所有采用描述性观察性设计、报告社区中抗抑郁药使用流行率的研究。纳入研究的选择（通过标题/摘要和全文筛选）和数据提取将由一对评审员独立进行。然后，我们将综合社区中个体使用抗抑郁药的流行率数据。如果可能，我们将进行荟萃分析以生成流行率汇总估计值。如果数据允许，我们将按抗抑郁药类别、年龄、性别、国家和其他社会人口学类别进行亚组分析。我们将使用 Joanna Briggs 研究所的批判性评估工具：报告流行率数据的检查表对每个纳入研究进行质量评估，以评估偏倚风险。DistillerSR 软件将用于管理本次评价。
由于本次评价不直接涉及人类或动物对象，因此不需要伦理批准。我们的系统评价结果将通过在同行评议期刊上发表、在精神卫生和药物流行病学国际会议上发表演讲以及在一般公众活动中发表来传播。
PROSPERO 注册号：CRD42021247423。
